Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Sales and Divestitures: 2019-2024

Historic Gains from Sales and Divestitures for Assembly Biosciences (ASMB) over the last 6 years, with Dec 2024 value amounting to $51,872.

  • Assembly Biosciences' Gains from Sales and Divestitures rose 20.92% to $51,872 in Q4 2024 from the same period last year, while for Dec 2024 it was $51,872, marking a year-over-year increase of 20.92%. This contributed to the annual value of $51,872 for FY2024, which is 20.92% up from last year.
  • Assembly Biosciences' Gains from Sales and Divestitures amounted to $51,872 in FY2024, which was up 20.92% from $42,898 recorded in FY2023.
  • Over the past 5 years, Assembly Biosciences' Gains from Sales and Divestitures peaked at $347,096 during FY2021, and registered a low of $42,898 during FY2023.
  • For the 3-year period, Assembly Biosciences' Gains from Sales and Divestitures averaged around $114,715, with its median value being $51,872 (2024).
  • Per our database at Business Quant, Assembly Biosciences' Gains from Sales and Divestitures skyrocketed by 102.36% in 2020 and then plummeted by 82.80% in 2023.
  • Assembly Biosciences' Gains from Sales and Divestitures (Yearly) stood at $297,133 in 2020, then grew by 16.82% to $347,096 in 2021, then declined by 28.15% to $249,376 in 2022, then slumped by 82.80% to $42,898 in 2023, then rose by 20.92% to $51,872 in 2024.